ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evotec Signs Two Deals With Sanofi

by Michael McCoy
August 17, 2015 | APPEARED IN VOLUME 93, ISSUE 32

The German contract research firm Evotec has formed two drug discovery agreements with Sanofi. In the first, Evotec and Apeiron Biologics are joining with Sanofi to develop small-molecule-based cancer immunotherapies. Evotec and Apeiron will get undisclosed research payments and could reap milestone payments of more than $200 million. In the second, Evotec and Sanofi will combine their know-how in human β cells to identify β-cell-active small molecules and biologics that could treat diabetes. Evotec will get $3 million up front plus milestones.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment